Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP

This article was originally published in The Tan Sheet

Executive Summary

U.S. Pharmacopeia soliciting suggestions as it sets its goals, strategies and policies from 2000 through 2005. Resolutions will be considered by USP Convention members during the quinquennial meeting April 12-16 in Washington, D.C. Guidance suggestions should build upon USP's preliminary strategic plan for 2000-2003, which lists among its goals establishment of compendial standards for dietary supplements and maintenance and establishment of new National Formulary monographs for the most commonly used excipients in dosage forms of pharmaceuticals, biologicals and dietary supplements. Also, USP's first monograph on a botanical dosage form (ginkgo biloba tablet) will appear in the November/December issue of Pharmacopeial Forum

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS090396

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel